Peptides for Surgery Recovery: Can Peptides Speed Post-Surgical Healing?

Key Takeaways

• Compounds covered: BPC-157, thymosin beta-4 (TB-500), GH secretagogues (GHRP-2, GHRP-6, ipamorelin), thymosin alpha-1
• Goal area: Post-surgical wound healing, inflammation reduction, and recovery support
• Evidence range: Ranges from one ex-US RCT signal in colorectal cancer surgery — thymosin alpha-1 for perioperative immune function, per Niu and colleagues in 2024 — and one human wound healing study of GHRP-6 by Mendoza Marí and colleagues in 2016, to preclinical-only evidence for BPC-157 and TB-500; no compound has completed a Phase 3 RCT with post-surgical healing as a primary endpoint in a US population
• Regulatory range: None of ipamorelin, GHRP-2, GHRP-6, thymosin alpha-1, BPC-157, or TB-500 is on the FDA 503A Category 1 list, has a USP monograph, or is a component of any FDA-approved drug — none qualifies for lawful 503A compounding in the US for a post-surgical healing indication. Following FDA's February 2026 action removing BPC-157 from the Category 2 interim bulks list, licensed 503A pharmacies do not have a recognized pathway to compound BPC-157 for human use.
• Key biomarkers for post-surgical recovery: hs-CRP, CBC with differential, IGF-1, albumin, comprehensive metabolic panel
• As of April 2026: No peptide in this list is FDA-approved as a post-surgical healing agent, and none is lawfully compoundable under Section 503A in the US for post-surgical recovery use. Some compounding pharmacies dispense these substances in reliance on interpretations that FDA has not formally endorsed.
• Bottom line: BPC-157 has a substantial preclinical surgical healing evidence base in animals; thymosin alpha-1 has the one available ex-US RCT signal in cancer surgery; any use requires physician oversight and acknowledgement of the regulatory status. This article is educational and is not intended to diagnose or treat any post-surgical condition.

Understanding Post-Surgical Healing: The Biology

Surgery creates controlled tissue trauma, incisions through skin, fascia, and underlying structures, that activates the standard wound healing cascade. This cascade proceeds through four sequential but overlapping phases: hemostasis (clot formation), inflammation (immune cell recruitment and debridement), proliferation (fibroblast activity, collagen synthesis, angiogenesis, granulation tissue formation), and remodeling (collagen cross-linking, scar maturation, tissue organization). Post-surgical recovery quality depends on how efficiently the biology moves through these phases.

Two compounding problems affect post-surgical recovery that peptide therapy is being studied to address. First, the surgical inflammatory response can exceed what is biologically necessary, particularly after major procedures, creating prolonged inflammatory burden that delays healing and suppresses immune function. Second, post-surgical catabolism: surgery triggers a stress response (mediated by cortisol, inflammatory cytokines, and reduced nutritional intake) that accelerates lean mass loss, which in turn impairs recovery speed and strength restoration. GH secretagogues address the second problem through IGF-1-mediated anabolic signaling; BPC-157 and TB-500 are studied for their capacity to address the first.

A 2022 review by Tresguerres and colleagues in the International Journal of Molecular Sciences reviewed GH's tissue-protective effects in aging, a relevant mechanistic reference for why GH-axis peptides are of research interest in catabolic-stress contexts including post-surgical recovery. Sikiric and colleagues, in Inflammopharmacology in 2024, reviewed BPC-157's proposed cytoprotective mechanisms including its studied effects on vascular failure and multiorgan inflammatory stress in animal models. In animal surgical models, vascular reconstruction at operated tissue sites has been studied for BPC-157 (via VEGF) and TB-500 (via Notch/NF-κB); these mechanisms are described in the preclinical literature for these compounds and have not been demonstrated in humans. Preclinical findings are research hypotheses, not clinical recommendations.

Peptides Studied for Surgery Recovery: A Quick Comparison

The following peptides have published evidence relevant to post-surgical recovery mechanisms. They are listed by strength of clinical evidence, from most-studied to least.

• Compound: Thymosin alpha-1
  Mechanism for post-surgical recovery: Proposed T-regulatory cell activity studied in perioperative immune contexts
  Evidence: One ex-US RCT in colorectal cancer surgery from Niu and colleagues in 2024; no Phase 3 RCT for general post-surgical recovery in US patients
  FDA status: Approved in some ex-US jurisdictions (e.g., as Zadaxin); not FDA-approved in the US. Not on the FDA 503A Category 1 list, no US USP monograph, not a component of any FDA-approved US drug — no active 503A statutory pathway for compounding thymosin alpha-1 in the US. Currently on the Category 2 interim list
  SP availability: Not available through Superpower for this use
  Route: Subcutaneous injection
• Compound: GH secretagogues (GHRP-2, GHRP-6, ipamorelin)
  Mechanism for post-surgical recovery: Proposed IGF-1 stimulation relevant to anabolic lean mass; macrophage polarization (GHRP-2) and wound healing signals (GHRP-6) studied in animal and small human studies
  Evidence: Human wound healing study for GHRP-6 from Mendoza Marí and colleagues in 2016; rat rotator cuff repair study for GHRP-2 from Li and colleagues in 2025; no Phase 3 RCT for surgical recovery
  FDA status: Not FDA-approved for post-surgical recovery. Ipamorelin: not on 503A Category 1 (FDA's 2020 PCAC review did not recommend Category 1 listing), no USP monograph, not a component of any FDA-approved drug; currently on Category 2 interim list. GHRP-2 and GHRP-6: never FDA-approved, not on Category 1, no USP monograph, not components of any FDA-approved drug; both on Category 2 interim list. No active 503A statutory pathway for any of these substances in the US
  SP availability: Not available through Superpower for post-surgical recovery
  Route: Subcutaneous injection
• Compound: BPC-157
  Mechanism for post-surgical recovery: Proposed nitric oxide-mediated anastomotic wound healing, pro-angiogenic support, and anti-nociceptive activity studied in animal models
  Evidence: Animal anastomosis and wound healing studies from Djakovic and colleagues in 2016, Klicek and colleagues in 2013, and Sikiric and colleagues in 2011; no human RCT
  FDA status: Not FDA-approved for any indication. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A. Following FDA's February 2026 action removing BPC-157 from the Category 2 interim bulks list, licensed 503A pharmacies do not have a recognized pathway to compound BPC-157 for human use
  SP availability: Not available through Superpower
  Route: Subcutaneous injection or oral (research contexts)
• Compound: TB-500 (thymosin beta-4)
  Mechanism for post-surgical recovery: Proposed anti-inflammatory activity and Notch/NF-κB-mediated angiogenesis studied in animal models
  Evidence: Animal and mechanistic studies from Dubé and colleagues in 2018, Bjørklund and colleagues in 2020, and Lv and colleagues in 2020; no human RCT
  FDA status: Not FDA-approved under 21 U.S.C. § 355. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A and not lawfully dispensable as a finished drug product in the US
  SP availability: Not available through Superpower
  Route: Subcutaneous injection

None of the compounds discussed in this article qualifies for lawful 503A compounding for a post-surgical healing indication in the US. Under FDA's intended use doctrine (21 CFR 201.128), "Research Use Only" labeling does not cure distribution for evident human consumption. Online sale of these compounds for human use generally falls outside FDA's approved-drug and 503A compounding pathways; such distribution has been the subject of FDA enforcement activity. Inclusion here is for educational context only.

Peptides Studied for Surgery Recovery: Individual Profiles

Each compound addresses a different aspect of post-surgical recovery biology and carries a different evidence base. None replaces standard post-surgical care. Each requires physician evaluation in the context of the specific surgical procedure and recovery trajectory.

BPC-157

BPC-157 is a synthetic 15-amino-acid pentadecapeptide. It is not FDA-approved for any indication. As of April 2026, BPC-157 is not on the FDA 503A Category 1 list, has no USP monograph, and is not a component of any FDA-approved drug — so it does not qualify for lawful 503A compounding under 21 U.S.C. § 353a(b)(1)(A). Following FDA's February 2026 action removing BPC-157 from the Category 2 interim bulks list, licensed 503A pharmacies do not have a recognized pathway to compound BPC-157 for human use. Removal from the Category 2 interim list does not equate to Category 1 eligibility. The post-surgical evidence for BPC-157 is primarily from animal gastrointestinal surgical models, where the compound has been studied at anastomotic sites.

Djakovic and colleagues, in the World Journal of Gastroenterology in 2016, reported that BPC-157 accelerated esophagogastric anastomosis healing in rats via a nitric oxide pathway, a direct preclinical citation for BPC-157's effects at surgically created tissue junctions in animals. Klicek and colleagues, in the Journal of Physiology and Pharmacology in 2013, reported that BPC-157 accelerated colon-to-colon anastomotic healing in rats, extending the anastomotic wound healing evidence in animals to colorectal surgical contexts. Sikiric and colleagues, in Current Pharmaceutical Design in 2011, reviewed BPC-157 in preclinical GI surgical contexts, establishing the narrative review foundation for the anastomotic healing research.

For the wound healing mechanism proposed for surgical incisions, Seiwerth and colleagues, in Frontiers in Pharmacology in 2021, reviewed BPC-157 and wound healing with emphasis on preclinical vascular and tissue repair mechanisms, documenting the VEGF-mediated angiogenesis described in animal studies. Brcic and colleagues, in the Journal of Physiology and Pharmacology in 2009, reported BPC-157 effects on VEGF-mediated angiogenesis in animal musculoskeletal healing. Gwyer and colleagues' 2019 review in Cell and Tissue Research covered BPC-157's preclinical musculoskeletal healing profile. Seiwerth and colleagues' 2018 review in Current Pharmaceutical Design documented BPC-157's interactions with angiogenic growth factors across diverse tissue types in preclinical models.

For the pain research dimension, Yuan and colleagues in 2026 reviewed BPC-157 tissue repair and pain research. Jung and colleagues, in the Journal of Dental Anesthesia and Pain Medicine in 2022, reported BPC-157's anti-nociceptive effects in a rodent incisional pain model. For smooth muscle recovery context, Staresinic and colleagues, in Biomedicines in 2022, reviewed BPC-157's effects on multiple muscle types in preclinical studies.

The Matek and colleagues 2026 review in Pharmaceuticals addressed BPC-157 at musculoskeletal tissue junctions in preclinical research relevant to orthopaedic research contexts. DeFoor and colleagues, in Arthroscopy in 2025, framed BPC-157 within regenerative medicine research. A 2026 review by Rahman and colleagues in JAAOS Global Research and Reviews contextualized peptide surgical recovery research within the orthopaedic pipeline. [Animal study evidence only; no completed human RCT for post-surgical healing]

As of April 2026, BPC-157 is not lawfully compoundable under Section 503A in the US. Not available through Superpower or any licensed prescriber for this use. A 2025 narrative review by McGuire and colleagues discussed BPC-157 benefits and risks in the research literature, and a 2025 systematic review by Vasireddi and colleagues in the HSS Journal noted the preclinical nature of available evidence. Mendias and colleagues' 2026 Sports Medicine review discussed safety framing for unapproved peptide use.

GH secretagogues (GHRP-2, GHRP-6, ipamorelin)

GH secretagogues are the compound class with human-level wound healing data in addition to preclinical evidence. Two distinct mechanistic pathways have been studied: anabolic lean mass preservation via IGF-1, and direct tissue repair activity in preclinical models.

For tissue repair research, Li and colleagues, writing in Arthroscopy in 2025, reported GHRP-2's rat rotator cuff repair findings, including decreased M1 macrophage production and histological changes at the tendon-bone interface — one of the closest available preclinical links between a GH secretagogue and a post-surgical healing signal. The macrophage polarization mechanism (shifting from pro-inflammatory M1 toward pro-healing M2 macrophages) is a research-stage observation in animals. Mendoza Marí and colleagues, in Plastic Surgery International in 2016, evaluated GHRP-6's effects on wound healing in humans, one of the few available human-level findings for a GH-releasing peptide in a post-surgical incision context. A 2022 review by Tresguerres and colleagues reviewed GH's mechanisms of action in the aging process across multiple organ systems, including muscle preservation research relevant to catabolic-stress contexts. [Human wound healing study (GHRP-6); animal model (GHRP-2); no Phase 3 RCT for surgical recovery]

GH secretagogues are not FDA-approved for post-surgical recovery, and any clinical use in this context would be off-label. Ipamorelin is not on the FDA 503A Category 1 list — FDA's 2020 PCAC review did not recommend ipamorelin for Category 1 listing — has no USP monograph, and is not a component of any FDA-approved drug; it currently sits on the Category 2 interim list. GHRP-2 and GHRP-6 have never been FDA-approved, are not on Category 1, have no USP monograph, and are not components of any FDA-approved drug; both sit on Category 2. There is no active 503A statutory pathway for any of these substances in the US. Some compounding pharmacies have historically dispensed ipamorelin in reliance on interpretations that FDA has not formally endorsed; its Category 2 interim listing reflects pending safety review rather than affirmative 503A eligibility. FDA's posture toward GHRP-2 and GHRP-6 compounding has been less permissive, and FDA has issued warning letters in connection with compounding-pharmacy distribution of GHRP-class secretagogues. Practice varies by pharmacy and state, but none of these substances is on a statutorily recognized 503A pathway. Safety and efficacy for post-surgical recovery have not been established through adequate and well-controlled clinical trials.

Thymosin alpha-1

Thymosin alpha-1 is a 28-amino-acid thymic peptide. In the post-surgical research context, its proposed relevance is immunological: surgery triggers significant immune suppression, and thymosin alpha-1's T-regulatory cell activity has been studied in relation to perioperative immune changes. An RCT by Niu and colleagues, published in Biotechnology and Genetic Engineering Reviews in 2024, examined thymalfasin's perioperative immune function findings in colorectal cancer surgery patients, reporting changes in immune markers and prognostic endpoints — the closest available human clinical data for any peptide evaluated in a surgical recovery endpoint. This is a single ex-US RCT in a cancer-surgery population and does not establish efficacy or safety of thymosin alpha-1 in general post-surgical recovery, non-cancer surgical populations, or US patients; the publication venue is also not a primary clinical surgery or oncology journal, which is relevant context when weighing this RCT's evidentiary strength. [Single ex-US RCT in cancer surgery; no Phase 3 RCT for general surgical recovery]

Thymosin alpha-1 (thymalfasin) is approved in some ex-US jurisdictions (e.g., as Zadaxin) but is not FDA-approved in the US. It is not on the FDA 503A Category 1 list, has no US USP monograph, and is not a component of any FDA-approved US drug. It currently sits on the Category 2 interim list. There is no active 503A statutory pathway for compounding thymosin alpha-1 in the US. Some compounding pharmacies have historically dispensed thymosin alpha-1 in reliance on interpretations that FDA has not formally endorsed. Not available through Superpower for this use.

TB-500 (thymosin beta-4)

Thymosin beta-4 is a 43-amino-acid peptide involved in actin sequestration and vascular development. In the post-surgical research context, its proposed relevance in animal studies spans two phases: post-operative inflammation and revascularization of disrupted tissue. Dubé and colleagues, in Expert Opinion on Biological Therapy in 2018, reviewed thymosin beta-4's tissue repair roles. Bjørklund and colleagues, in Current Medicinal Chemistry in 2020, described TB-4 as a multi-faceted repair protein in cardiac injury contexts. Lv and colleagues, in the International Journal of Molecular Medicine in 2020, reported TB-4 induced Notch/NF-κB angiogenesis in a critical limb ischemia mouse model. [Animal study; no human RCT for post-surgical recovery]

TB-500 is not FDA-approved as a drug under 21 U.S.C. § 355. It is not on the FDA 503A Category 1 list, has no USP monograph, and is not a component of any FDA-approved drug — meaning it is not lawfully compoundable under Section 503A and not lawfully dispensable as a finished drug product in the US. Not available through Superpower. Inclusion is for educational context only.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry different regulatory statuses for post-surgical recovery applications.

• Thymosin alpha-1: Approved in some ex-US jurisdictions (e.g., as Zadaxin); not FDA-approved in the US. Not on the FDA 503A Category 1 list, no US USP monograph, not a component of any FDA-approved US drug. Currently on the Category 2 interim list. No active 503A statutory pathway for compounding thymosin alpha-1 in the US. One ex-US RCT signal in colorectal cancer surgery.
• GH secretagogues (GHRP-2, GHRP-6, ipamorelin): Not FDA-approved for any indication in the US. Ipamorelin is not on 503A Category 1 (FDA's 2020 PCAC review did not recommend Category 1 listing) and sits on Category 2 interim. GHRP-2 and GHRP-6 have never been FDA-approved and sit on Category 2 interim. None has a USP monograph or is a component of any FDA-approved drug — no active 503A statutory pathway. Not available through Superpower for post-surgical recovery.
• BPC-157: Not FDA-approved for any indication. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A. Following FDA's February 2026 action removing BPC-157 from the Category 2 interim bulks list, licensed 503A pharmacies do not have a recognized pathway to compound BPC-157 for human use. Removal from the Category 2 interim list does not equate to Category 1 eligibility.
• TB-500 (thymosin beta-4): Not FDA-approved under 21 U.S.C. § 355. Not on the FDA 503A Category 1 list, no USP monograph, not a component of any FDA-approved drug — not lawfully compoundable under Section 503A and not lawfully dispensable as a finished drug product in the US.

No FDA-approved indication exists for any compound discussed in this article for post-surgical recovery. Any use in humans for this purpose is investigational and, for the substances without a valid 503A pathway, outside lawful US compounding. Under FDA's intended use doctrine (21 CFR 201.128), "Research Use Only" labeling does not cure distribution for evident human consumption. Online sale of BPC-157 or TB-500 for human use generally falls outside FDA's approved-drug and 503A compounding pathways; such distribution has been the subject of FDA enforcement activity. Their presence in this article is for educational context only.

Considerations When Comparing Peptides for Surgery Recovery

Post-surgical recovery is not a single biological event. It is a sequence of overlapping phases across different tissue types, compounded by systemic physiological stress. Selecting any adjunct compound must account for the specific surgery, the tissue types involved, the phase of recovery, and the full medication list.

Surgery type and tissue involved: GI surgical recovery involves anastomotic wound healing; orthopaedic surgical recovery involves tendon, ligament, and bone-to-soft-tissue junctions; abdominal surgery involves smooth muscle healing. BPC-157's evidence spans GI anastomotic, orthopaedic, and smooth muscle contexts, but no single compound addresses all post-surgical tissue types equally. A provider will evaluate which tissue types were operated on before considering any adjunct.

Recovery phase (research hypotheses only): Preclinical researchers have proposed that, if translated to humans, TB-500's anti-inflammatory activity and thymosin alpha-1's immune-regulatory effects would be most relevant in the early inflammatory phase (days 1–5), and that BPC-157's angiogenic and fibroblast-related activity would be most relevant in the proliferative phase (days 5–21). GH secretagogue proposals relate to anabolic effects on lean mass throughout recovery. No human protocol has been established for any of these compounds in post-surgical contexts. These phase mappings are research hypotheses, not clinical recommendations. No FDA-approved indication exists for any compound discussed in this article in post-surgical recovery, and for the substances without a valid 503A pathway, any use would be outside lawful US compounding.

Drug interaction risk: Post-surgical patients are commonly on anticoagulants, antibiotics, analgesics, and anesthesia clearance medications. Drug interaction data between any investigational peptide and post-surgical medication classes do not exist. This is not a theoretical risk; it is an active unknown that only a physician can evaluate against the specific post-surgical medication list.

Immune status post-surgery: Major surgery suppresses immune function, increasing infection risk. Thymosin alpha-1's proposed immune-related activity has been studied in this context, but adding immune-active compounds to a post-surgical patient on concurrent antibiotics or immunosuppressants requires specialist oversight.

This is not an exhaustive list. A licensed surgeon and post-operative care team must be informed and involved in any decision to introduce adjunct compounds during recovery. Mayfield and colleagues' 2026 primer in the American Journal of Sports Medicine discussed physician-supervised protocols as the appropriate clinical context for any research use of injectable peptides in surgical recovery.

Safety Considerations

Post-surgical patients represent a population where the theoretical risks of investigational peptides are elevated relative to elective use in otherwise healthy adults. Organ function is frequently compromised immediately post-surgery, altering peptide metabolism. Surgical wounds are potential routes for infection that injectable peptides could interact with. Immune function is suppressed. And concurrent medications create an interaction landscape that has not been studied. Mendias and colleagues, in their 2026 Sports Medicine review, discussed potential for serious harm with unapproved peptide use, a concern that applies with particular force in post-surgical contexts.

Contraindications that apply broadly to peptide therapy for post-surgical recovery include:

• Active post-surgical infection or anastomotic leak: pro-angiogenic and pro-healing compounds are contraindicated when active infection or surgical complication is present
• Active or history of hormone-sensitive malignancy (GH secretagogues): GH/IGF-1 signaling has theoretical proliferative implications documented in approved GH product labels (e.g., Genotropin, Humatrope); oncological clearance is standard before any off-label secretagogue consideration
• Active or history of any malignancy (BPC-157): no FDA-approved labeling exists; the angiogenic / VEGF-related mechanism described in preclinical studies is a theoretical safety concern with no established clinical framework
• Concurrent use of anticoagulants: injectable peptides carry injection-site bleeding risk; interaction with anticoagulant therapy has not been studied
• Pregnancy: no reproductive safety data exist for any compound in this list
• Organ transplant recipients: immunomodulatory compounds are not appropriate without transplant team oversight

For compound-specific safety profiles, consult your surgeon and licensed healthcare provider, and review the ISI block at the bottom of this page.

What to Test Before Starting Peptides for Surgery Recovery

Regardless of which compound is being discussed, baseline biomarker testing provides the objective foundation for evaluating recovery trajectory. For post-surgical contexts, these tests also establish whether organ function is adequate for any additional compound, a safety consideration that applies with particular force in the days and weeks following major surgery.

• Comprehensive metabolic panel: Liver enzymes (ALT, AST) and kidney function (creatinine, eGFR) are mandatory safety baselines before any injectable compound post-surgically. Organ function is frequently altered immediately after surgery. Testing eGFR and hepatic markers establishes the safety threshold before any additional compound is introduced.
• hs-CRP: A baseline and serial hs-CRP measurement tracks the inflammatory trajectory of recovery. Post-surgical CRP normally peaks at days 2–3 and falls progressively. Failure to normalize is a clinical signal; a baseline makes any subsequent reading interpretable.
• CBC with differential: Immune cell profile and general health status. Essential before any compound with immune-active mechanisms (thymosin alpha-1) and for infection surveillance in the post-operative period. Baseline CBC enables comparison against post-operative values.
• IGF-1: GH axis status and anabolic signaling capacity. Testing IGF-1 levels before starting any GH secretagogue protocol is standard clinical practice. In a recovery context, it also reflects the anabolic capacity available to support tissue repair and lean mass preservation.
• Albumin: Serum albumin reflects nutritional status and is a sensitive marker of the catabolic state that follows major surgery. Low albumin is associated with impaired wound healing and increased complication risk, and is a key context variable before adding any compound to a recovery protocol.
• Vitamin D (25-hydroxy): Vitamin D supports immune function and tissue repair. Deficiency is common and addressable. Baseline 25-hydroxy vitamin D establishes whether correction should be prioritized before any additional compound is considered.

Testing for inflammation and recovery biomarkers provides the most relevant objective baseline for any post-surgical recovery protocol, and creates the reference point that makes subsequent changes interpretable.

How to Access These Peptides Safely

As of April 2026, none of the compounds discussed in this article qualifies for lawful 503A compounding for a post-surgical healing indication in the US. Ipamorelin, GHRP-2, GHRP-6, and thymosin alpha-1 are not on the 503A Category 1 list, have no US USP monograph, and are not components of any FDA-approved US drug; all currently sit on the Category 2 interim list. Some compounding pharmacies have historically dispensed ipamorelin in reliance on interpretations that FDA has not formally endorsed; FDA's posture toward GHRP-2 and GHRP-6 compounding has been less permissive, and FDA has issued warning letters in connection with compounding-pharmacy distribution of GHRP-class secretagogues. Practice varies by pharmacy and state, but none of these substances is on a statutorily recognized 503A pathway. In a post-surgical context, any discussion of adjunct compounds must involve the operating surgeon and the post-operative care team — not a telehealth prescription from a separate provider unfamiliar with the surgical details. The surgical context introduces variables (tissue disruption, medication interactions, altered physiology) that require integrated clinical management.

BPC-157 and TB-500 are not lawfully compoundable or prescribable in the US. Under FDA's intended use doctrine (21 CFR 201.128), "Research Use Only" labeling does not cure distribution for evident human consumption. Online sale of BPC-157 or TB-500 for human use generally falls outside FDA's approved-drug and 503A compounding pathways; such distribution has been the subject of FDA enforcement activity. Introducing unregulated injectables into a post-surgical patient, where immune function is compromised and infection risk is elevated, carries risks that are substantially higher than in elective wellness contexts. Mendias and colleagues' 2026 Sports Medicine review discussed these risks for the category.

Understanding Your Baseline

Post-surgical recovery is time-sensitive and measurable. CRP trajectories, immune reconstitution, and anabolic recovery can all be tracked objectively. Knowing your baseline values before surgery, or establishing them as early as safely possible in recovery, means that any deviation from expected recovery trajectory is detectable, and any intervention can be evaluated against a reference point rather than a clinical impression.

That principle, test first, then decide, is central to Superpower's approach to preventive health. Whether the conversation with your post-surgical care team leads to a standard recovery protocol, a nutritional optimization plan, or a supervised adjunct compound, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

BPC-157 is not approved by the FDA for any medical use. As of April 2026, BPC-157 is not on the FDA 503A Category 1 list, has no USP monograph, and is not a component of any FDA-approved drug — it is not lawfully compoundable under Section 503A. Following FDA's February 2026 action removing BPC-157 from the Category 2 interim bulks list, licensed 503A pharmacies do not have a recognized pathway to compound BPC-157 for human use. Removal from the Category 2 interim list does not equate to Category 1 eligibility. Research on BPC-157 in post-surgical contexts is limited to animal studies, including gastrointestinal anastomotic healing models. Safety, efficacy, appropriate dosing, drug interactions with post-surgical medications, and long-term effects for post-surgical recovery have not been established. BPC-157 is not prescribed, compounded, or dispensed through Superpower.

TB-500 (thymosin beta-4) is not approved by the FDA for any medical use. It is not FDA-approved as a drug under 21 U.S.C. § 355, is not on the FDA 503A Category 1 list, has no USP monograph, and is not a component of any FDA-approved drug — meaning it is not lawfully compoundable under Section 503A or lawfully dispensable as a finished drug product in the US. Research is limited to laboratory and animal studies. Safety, efficacy, dosing, and long-term effects in humans have not been established. TB-500 is not prescribed, compounded, or dispensed through Superpower.

GH secretagogues (including ipamorelin, GHRP-2, GHRP-6) are not FDA-approved for any indication in the US. Their use for post-surgical recovery would be off-label and requires individualized physician evaluation. Ipamorelin is not on 503A Category 1 (FDA's 2020 PCAC review did not recommend Category 1 listing), has no USP monograph, and is not a component of any FDA-approved drug; it currently sits on Category 2 interim. GHRP-2 and GHRP-6 have never been FDA-approved, are not on Category 1, have no USP monograph, and are not components of any FDA-approved drug; both sit on Category 2 interim. There is no active 503A statutory pathway for any of these substances in the US. IGF-1 monitoring is standard during any off-label secretagogue consideration. Contraindicated in acromegaly, active malignancy, and pregnancy. Drug interactions with post-surgical medications have not been studied. Safety and efficacy for post-surgical recovery have not been established through adequate and well-controlled clinical trials.

Thymosin alpha-1 (thymalfasin) is approved in some ex-US jurisdictions (e.g., as Zadaxin) but is not FDA-approved in the US. It is not on the 503A Category 1 list, has no US USP monograph, and is not a component of any FDA-approved US drug; it currently sits on the Category 2 interim list. There is no active 503A statutory pathway for compounding thymosin alpha-1 in the US. One ex-US RCT signal exists in a colorectal cancer surgery population (Niu et al., 2024); this is a single RCT in a cancer-surgery population and does not establish efficacy or safety in general post-surgical recovery or US patients. Safety and efficacy for general post-surgical recovery have not been established. Not currently available through Superpower for this use.

Post-surgical care requires physician supervision. Do not introduce any investigational compound during recovery without consulting your surgeon and post-operative care team. This article does not constitute medical advice. Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Disclaimer: This article discusses multiple peptide compounds studied in post-surgical recovery contexts. None of the compounds (BPC-157, TB-500, ipamorelin, GHRP-2, GHRP-6, thymosin alpha-1) is FDA-approved as a post-surgical healing agent, and none has an active 503A statutory pathway in the US for that use. Post-surgical use of any investigational compound requires surgeon and care team involvement. This educational content is editorially independent and is not intended to diagnose or treat any post-surgical condition.